High-dose radiotherapy for the treatment of inoperable non-small cell lung cancer Journal Article

  


Authors: Sura, S.; Yorke, E.; Jackson, A.; Rosenzweig, K. E.
Article Title: High-dose radiotherapy for the treatment of inoperable non-small cell lung cancer
Abstract: Purpose:: Local failure continues to be a major cause of mortality in patients with inoperable nonĝ€"small cell lung cancer (NSCLC) treated with radiation therapy. Dose escalation is one method of improving local control. We investigated whether high-dose radiotherapy enhances outcomes in patients with inoperable NSCLC. MATERIALS AND METHODS:: Eighty-two patients with inoperable NSCLC stage Iĝ€"IIIB were treated with three-dimensional conformal radiotherapy to doses of ĝ‰¥80 Gy. Patients were divided into 2 groups based on stage: those with stage I/II disease (55 patients) and those with stage III (IIIA or IIIB) disease (27 patients). RESULTS:: The 5-year local control and overall survival rates for the patients with stage I/II disease were 67% and 36%, respectively, with a median survival time of 41 months. For the patients with stage III disease, 5-year local control and overall survival rates were observed to be 39% and 31%, respectively, with a median survival time of 32 months. CONCLUSIONS:: Our data show a favorable 5-year overall survival rate (36%) with an acceptable toxicity profile in patients with early-stage NSCLC treated to doses of ĝ‰¥80 Gy using three-dimensional conformal radiotherapy. Sequential chemotherapy combined with high-dose radiation gave survival rates equivalent to those seen with concurrent chemoradiation therapy in locally advanced disease. The overall survival and local control rates observed among patients with all stages of disease are consistent with and comparable to results from other dose-escalation studies reported in the literature. Copyright © 2007 by Lippincott Williams & Wilkins.
Keywords: cancer chemotherapy; cancer survival; controlled study; treatment outcome; survival rate; major clinical study; overall survival; fatigue; mortality; multimodality cancer therapy; recommended drug dose; skin toxicity; cancer adjuvant therapy; cancer radiotherapy; radiation dose; nuclear magnetic resonance imaging; positron emission tomography; follow up; antineoplastic agent; computer assisted tomography; lung toxicity; tumor volume; esophagitis; lung non small cell cancer; nausea; carcinoma, non-small-cell lung; lung neoplasms; radiotherapy dosage; clinical assessment; lung tumor; survival time; disease severity; cardiotoxicity; fluorodeoxyglucose f 18; local control; maximum tolerated dose; cancer control; aspiration biopsy; patient positioning; mediastinoscopy; radiation pneumonia; nonsmall cell lung cancer; dose escalation; threedimensional conformal radiotherapy
Journal Title: The Cancer Journal
Volume: 13
Issue: 4
ISSN: 1528-9117
Publisher: Lippincott Williams & Wilkins  
Date Published: 2007-07-01
Start Page: 238
End Page: 242
Language: English
DOI: 10.1097/PPO.0b013e31813ffd7b
PUBMED: 17762758
PROVIDER: scopus
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-35748950168&partnerID=40&md5=1a67eb1af9ba989bdc41ae86084339d6
Notes: --- - "Cited By (since 1996): 9" - "Export Date: 17 November 2011" - "CODEN: CAJOC" - "Source: Scopus"
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Sonal Sura
    6 Sura
  2. Kenneth E Rosenzweig
    165 Rosenzweig
  3. Andrew Jackson
    253 Jackson
  4. Ellen D Yorke
    450 Yorke
Related MSK Work